Online citations, reference lists, and bibliographies.
← Back to Search

Mathematical Modelling Of The Role Of Mucosal Vaccine On The Within-host Dynamics Of Chlamydia Trachomatis.

M. D. Akinlotan, D. Mallet, R. Araujo
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
A mathematical model of the within-host replicative dynamics of C. trachomatis infection and its interactions with the immune system, in the presence of a mucosal vaccine, is presented. Our aim is to estimate the requisite efficacy of an efficacious mucosal vaccine that could promote a stable disease-free state in vivo. Sensitivity analysis was used to quantify how variability in the model parameters influence the value of the disease threshold R0. This shows that the two most important factors to be considered for achieving a disease-free state state in vivo, based on their influence on R0, are the efficacy of the Chlamydia vaccine, and the rate at which the humoral immune response protects healthy epithelial cells from infection. Numerical simulations of the model show that a vaccine with a minimum efficacy of 86% may be required for the in vivo control of Chlamydia burden. Such effective but imperfect Chlamydia vaccine could confer long-term protective immunity to genital Chlamydia infections. Conditions under which lower vaccine efficacies may suffice are also explored.
This paper references
10.2307/2308959
Ordinary Differential Equations.
N. G. Parke (1958)
10.2307/2316346
Ordinary Differential Equations.
R. Redheffer (1971)
10.1007/978-3-319-27200-9
Stability Analysis of Nonlinear Systems
V. Lakshmikantham (1988)
Lakshmikantham (1989)
10.1177/875647939000600106
Interpretation of the Correlation Coefficient: A Basic Review
Richard Taylor (1990)
10.1016/0002-9343(91)90396-F
Azithromycin in the treatment of uncomplicated genital chlamydial infections.
W. Stamm (1991)
10.1056/NEJM199209243271304
A Controlled Trial of a Single Dose of Azithromycin for the Treatment of Chlamydial Urethritis and Cervicitis
David H. Martin (1992)
10.1128/AAC.37.9.1746
In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae
A. Ağaçfidan (1993)
10.2307/1403510
Sensitivity and Uncertainty Analysis of Complex Models of Disease Transmission: an HIV Model, as an Example
S. Blower (1994)
10.1096/fasebj.8.13.7926369
Cytokine production by epithelial cells 1
A. Stadnyk (1994)
10.1093/OXFORDJOURNALS.EPIREV.A036147
Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies.
G. Comstock (1994)
10.1016/0264-410X(95)80022-6
A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections.
Michael de la Maza (1995)
10.1155/1998/395297
T lymphocyte immunity in host defence against Chlamydia trachomatis and its implication for vaccine development.
X. Yang (1998)
10.1128/IAI.66.11.5457-5461.1998
Gamma Interferon Production by Cytotoxic T Lymphocytes Is Required for Resolution of Chlamydia trachomatis Infection
M. Lampe (1998)
Chlamydia trachomatisinfections
Schachter (1999)
10.1053/SPID.2002.127201
The intracellular life of chlamydiae.
M. Hammerschlag (2002)
10.1016/S0025-5564(02)00108-6
Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission.
P. van den Driessche (2002)
10.1073/pnas.242358099
In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: Why are CD4+ but not CD8+ T cells depleted?
R. Ribeiro (2002)
10.1016/S1369-5274(02)00291-6
T cell responses to Chlamydia trachomatis.
W. P. Loomis (2002)
10.1016/S0025-5564(02)00180-3
A mathematical model for the investigation of the Th1 immune response to Chlamydia trachomatis.
D. P. Wilson (2003)
10.1016/S0264-410X(02)00677-1
Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis.
F. Eko (2003)
10.21914/ANZIAMJ.V45I0.883
Mathematical Modelling of Chlamydia
David P. Wilson (2004)
10.1016/J.JTBI.2003.09.010
A model of neutralization of Chlamydia trachomatis based on antibody and host cell aggregation on the elementary body surface.
D. P. Wilson (2004)
10.1016/J.BULM.2003.09.001
Use of a quantitative gene expression assay based on micro-array techniques and a mathematical model for the investigation of chlamydial generation time
David P. Wilson (2004)
10.1016/J.FEMSRE.2005.03.002
The chlamydial developmental cycle.
Yasser M. Abdelrahman (2005)
10.1038/nri1551
Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine
R. Brunham (2005)
10.1016/J.JTBI.2005.08.002
A cellular automata model of tumor-immune system interactions.
D. Mallet (2006)
10.1136/sti.2005.019158
The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection
P. Horner (2006)
10.1007/S11538-005-9024-1
Type III Secretion, Contact-dependent Model for the Intracellular Development of Chlamydia
D. P. Wilson (2006)
10.1186/1471-2180-8-5
Spatial constraints within the chlamydial host cell inclusion predict interrupted development and persistence
A. Hoare (2007)
10.1111/j.1365-2567.2007.02608.x
Live‐attenuated influenza viruses as delivery vectors for Chlamydia vaccines
Q. He (2007)
10.1002/PAMM.200700031
A novel cellular automata-partial differential equation model for understanding chlamydial infection and ascension of the female genital tract
D. Mallet (2007)
10.1186/1742-4682-5-4
Sampling and sensitivity analyses tools (SaSAT) for computational modelling
A. Hoare (2007)
10.1515/jiip.2007.013
Sensitivity analysis and parameter estimation for a model of Chlamydia Trachomatis infection
J. Burns (2007)
10.1136/sti.2007.027938
Epidemiology of chlamydial infection: are we losing ground?
M. Rekart (2008)
10.1007/978-1-4020-8412-6_16
Immunity Against Chlamydia trachomatis
E. Marks (2008)
10.1128/JB.00293-09
Kinematics of Intracellular Chlamydiae Provide Evidence for Contact-Dependent Development
David P. Wilson (2009)
10.1111/j.1574-695X.2008.00493.x
A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin.
E. Ekong (2009)
10.1111/j.1574-695X.2009.00596.x
Chlamydial infection and spatial ascension of the female genital tract: a novel hybrid cellular automata and continuum mathematical model.
D. Mallet (2009)
10.1095/biolreprod.108.073833
Chlamydia Infection Causes Loss of Pacemaker Cells and Inhibits Oocyte Transport in the Mouse Oviduct1
R. Dixon (2009)
10.1016/j.jri.2009.07.013
The mucosal immune response to Chlamydia trachomatis infection of the reproductive tract in women.
T. Agrawal (2009)
10.1371/journal.pone.0006886
Immunobiological Outcomes of Repeated Chlamydial Infection from Two Models of Within-Host Population Dynamics
D. Vickers (2009)
10.1086/605411
Role of T lymphocytes in the pathogenesis of Chlamydia disease.
J. Igietseme (2009)
Mathematical Modelling of the Interaction of Chlamydia Trachomatis with the Immune System
Masoumeh Bagher Oskouei (2010)
10.1084/jem.20090858
Dynamic T cell migration program provides resident memory within intestinal epithelium
D. Masopust (2010)
10.4161/hv.6.8.12299
Development of a Chlamydia trachomatis T cell Vaccine
Karuna P. Karunakaran (2010)
10.1080/08898480.2011.564560
Immune Response and Imperfect Vaccine in Malaria Dynamics
Ashrafi M. Niger (2011)
10.1093/cid/ciq074
Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial.
J. Schwebke (2011)
10.5402/2011/436936
Immunopathogenesis in Chlamydia trachomatis Infected Women
M. Mascellino (2011)
10.1097/OLQ.0b013e318227a366
Questioning azithromycin for chlamydial infection.
H. Handsfield (2011)
10.1586/erv.11.139
Chlamydia vaccines: recent developments and the role of adjuvants in future formulations
J. Igietseme (2011)
Chlamydia trachomatis infections: screening, diagnosis, and management.
R. Mishori (2012)
10.1093/IMAMAT/HXQ057
Mathematical study of in-host dynamics of Chlamydia trachomatis
O. Sharomi (2012)
10.1136/sextrans-2011-050385
Azithromycin antimicrobial resistance and genital Chlamydia trachomatis infection: duration of therapy may be the key to improving efficacy
P. Horner (2012)
10.1093/infdis/jit094
Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection.
W. Geisler (2013)
10.1128/AAC.01405-13
Differential Susceptibilities to Azithromycin Treatment of Chlamydial Infection in the Gastrointestinal Tract and Cervix
Laxmi Yeruva (2013)
10.1186/1471-2334-13-379
A cohort study of Chlamydia trachomatis treatment failure in women: a study protocol
J. Hocking (2013)
10.1007/s11538-013-9891-9
A Mathematical Model of Chlamydial Infection Incorporating Movement of Chlamydial Particles
D. Mallet (2013)
World Health Organisation. Immunization, Vaccines, and Biologicals
WHO (2013)
10.1186/s12865-014-0056-x
Vibrio cholerae ghosts (VCG) exert immunomodulatory effect on dendritic cells for enhanced antigen presentation and induction of protective immunity
F. Eko (2014)
10.1093/cid/ciu220
Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials.
F. Kong (2014)
10.1016/j.tpb.2014.01.005
The arrested immunity hypothesis in an immunoepidemiological model of Chlamydia transmission.
D. Vickers (2014)
10.1016/j.vaccine.2013.08.020
Development status and future prospects for a vaccine against Chlamydia trachomatis infection.
L. Hafner (2014)
Regulatory and public health challenges for vaccines inducing modest efficacy
Smith (2014)
Centers for Disease Control and Prevention: Sexually Transmitted Disease Surveillance 2013
CDC (2014)
World Health Organisation: Report on Global Sexually Transmitted Infection Surveillance 2013
WHO (2014)
10.1126/science.aac6528
A Chlamydia vaccine on the horizon
R. Brunham (2015)
10.1517/14656566.2015.999041
Treatment of chlamydial infections: 2014 update
S. Kohlhoff (2015)
10.2147/VDT.S69487
Development of a vaccine for Chlamydia trachomatis : challenges and current progress
L. Hafner (2015)
10.1126/science.aaa8205
A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells
G. Stary (2015)
10.1111/2049-632X.12203
Target cell limitation constrains chlamydial load in persistent infections: results from mathematical modelling applied to mouse genital tract infection data.
A. Craig (2015)
Centers for Disease Control and Prevention: Sexually Transmitted Disease Surveillance 2014
CDC (2015)
10.1128/CVI.00543-16
Update on Chlamydia trachomatis Vaccinology
L. M. de la Maza (2017)
10.1080/14760584.2018.1435279
Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles
Rajnish Sahu (2018)
10.1016/S1473-3099(19)30279-8
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
S. Abraham (2019)
10.1371/journal.pcbi.1006646
Epithelial stratification shapes infection dynamics
C. Murall (2019)
10.1016/j.amc.2019.124899
An optimal control model of the treatment of chronic Chlamydia trachomatis infection using a combination treatment with antibiotic and tryptophan
M. D. Akinlotan (2020)



Semantic Scholar Logo Some data provided by SemanticScholar